Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing a novel approach to hard-to-treat cancers through the development of Polynucleotide Kinase Phosphatase (PNKP) inhibitors, a class of DNA Damage Response (DDR) therapies that disrupt cancer cells' ability to repair damaged DNA. The company recently achieved a key manufacturing milestone by successfully advancing toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010.
This development is significant because many cancers rely on DNA repair mechanisms to survive conventional treatments like radiation and chemotherapy. According to the press release, cancers frequently exhibit defective repair of damaged DNA, leading to mutations that drive unchecked growth, immune evasion, and metastasis. While conventional DNA-damaging therapies can overwhelm a cancer's limited repair capacity, some tumors retain sufficient repair ability to resist these treatments at doses patients can tolerate. PNKP inhibitors like ONC010 aim to block a critical enzyme in the repair pathway, potentially making cancer cells more vulnerable to existing therapies.
To support further development, Onco-Innovations has signed a Letter of Intent with Nanosoft Polymers, which is expected to aid in polymer development, drug delivery optimization, and formulation work for the ONC010 program. This collaboration could enhance the drug's efficacy and stability, addressing key challenges in bringing DDR inhibitors to clinical use.
The implications of this announcement are noteworthy for the oncology field. If successful, ONC010 could offer a new treatment option for patients with cancers that are resistant to standard therapies, potentially improving outcomes in indications with high unmet medical need. The advancement to kilogram-scale production also suggests the company is preparing for preclinical and clinical studies, moving closer to human trials.
Onco-Innovations is positioning itself within the rapidly evolving DDR therapy space, which has gained attention for its potential to target tumor-specific vulnerabilities. The company's focus on PNKP distinguishes it from other DDR approaches, such as PARP inhibitors, which have already shown promise in certain cancers. For investors and industry observers, ONC010's progress represents a step forward in the pipeline, though further data from animal models and eventual clinical trials will be critical to assess its true potential.
For ongoing updates, the company's newsroom is available at ibn.fm/ONNVF. Additional information about BioMedWire, which disseminated this release, can be found at https://www.BioMedWire.com.
